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Abstract
Cyclin-dependent kinase 7 (CDK7) is a protein kinase that plays a major role in tran-
scription initiation. Yes-associated protein (YAP) is a main effector of the Hippo/
YAP signalling pathway. Here, we investigated the role of CDK7 on YAP regulation 
in human malignant pleural mesothelioma (MPM). We found that in microarray sam-
ples of human MPM tissue, immunohistochemistry staining showed correlation be-
tween the expression level of CDK7 and YAP (n = 70, r = .513). In MPM cells, CDK7 
expression level was significantly correlated with GTIIC reporter activity (r = .886, 
P = .019). Inhibition of CDK7 by siRNA decreased the YAP protein level and the GTIIC 
reporter activity in the MPM cell lines 211H, H290 and H2052. Degradation of the 
YAP protein was accelerated after CDK7 knockdown in 211H, H290 and H2052 
cells. Inhibition of CDK7 reduced tumour cell migration and invasion, as well as tum-
orsphere formation ability. Restoration of the CDK7 gene rescued the YAP protein 
level and GTIIC reporter activity after siRNA knockdown in 211H and H2052 cells. 
Finally, we performed a co-immunoprecipitation analysis using an anti-YAP antibody 
and captured the CDK7 protein in 211H cells. Our results suggest that CDK7 inhibi-
tion reduces the YAP protein level by promoting its degradation and suppresses the 
migration and invasion of MPM cells. Cyclin-dependent kinase 7 may be a promising 
therapeutic target for MPM.
K E Y W O R D S
cyclin-dependent kinase 7, Hippo pathway, malignant pleural mesothelioma, yes-associated 
protein
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1  | INTRODUC TION
Malignant pleural mesothelioma (MPM) is highly invasive and has a 
poor prognosis. The pathogenesis of MPM is mainly related to asbestos 
exposure, but genetic susceptibility is also receiving increased atten-
tion.1-3 Overall, the current recommended treatment is a combination 
of surgery, radiation therapy, chemotherapy and immunotherapy, but 
median overall survival remains only approximately 7 months.4,5 Novel 
therapeutic targets for patients with MPM are needed.
Yes-associated protein (YAP), a transcriptional coactivator, is 
the major regulatory effector in the Hippo pathway, and its over-
expression contributes to the development of many cancers and 
resistance to anticancer drugs.6-8 Therefore, at present, YAP is a 
new anticancer research hotspot. Our previous study confirmed 
that YAP is involved in the occurrence and development of MPM.9 
In the Hippo pathway, NF2, LATS1/2, MST1/2 and SAV1 regu-
late the expression of YAP, and the inactivation of these tumour 
suppressor genes leads to sustained nuclear YAP expression and 
tumorigenicity.10-13 In addition to these classic Hippo signals, 
some other cellular pathways and components are also involved 
in YAP regulation, including RhoA/ROCK, GTPase, alpha-catenin, 
Cyclin-dependent kinase 1 (CDK1) and G-protein coupled recep-
tors (GPCRs).14-18 However, the complex regulation of YAP is still 
unclear. An in-depth understanding of the regulatory mechanisms 
of YAP in MPM cells would provide a foundation for developing 
multi-drug combined targeted therapy.
Cyclin-dependent kinase 7 is a protein serine/threonine kinase 
that belongs to the cyclin-dependent kinase family. Different from 
other CDKs, in addition to regulating the cell cycle, CDK7 also plays 
an important role in interfering with transcription primarily by phos-
phorylating RNA polymerase II and transcription factors, which 
was confirmed in the study of CDK7 small molecule inhibitors in a 
variety of cancer types, including breast, lung, neuroblastoma and 
leukaemia.19 However, the challenging question of how CDK7 ac-
tivity is integrated into transcription regulation remains largely un-
answered. Cyclin-dependent kinase 7 expression in breast cancer is 
significantly negatively correlated with poor prognostic factors and 
survival rate.20
Interestingly, both CDK7 and YAP play specific roles in tumori-
genesis in the nucleus and consistently regulate cell proliferation and 
affect prognosis.9,19 However, the relationship between CDK7 and 
YAP has not yet been described. Here, we hypothesized that CDK7 
inhibition down-regulates YAP expression and sought to answer 
whether CDK7 is involved in regulating YAP expression in human 
MPM.
2  | MATERIAL S AND METHODS
2.1 | Cell culture
The human MPM cell lines 211H (biphasic), H290 (unknown), 
H2452 (epithelial), H2052 (sarcomatoid), MS-1 (epithelial) and 
H28 (sarcomatoid) were obtained from the American Type Culture 
Collection. The human normal mesothelial cell line LP9 was pur-
chased from the Cell Culture Core Facility at Harvard University 
(Boston, MA, USA). Cell lines were maintained in RPMI-1640, 
except LP-9, which was maintained in M199 supplemented with 
15% (v/v) heat-inactivated FBS, 10 ng/mL EGF, 0.4 μg/mL hydro-
cortisone and penicillin (100 IU/mL). RPMI-1640 media were sup-
plemented with 10% heat-inactivated foetal bovine serum and 
penicillin (100 mg/mL). All cells were cultured at 37°C in a humid 
incubator with 5% CO2.
2.2 | Tissue samples and immunohistochemistry 
(IHC)
Fresh human MPM tissues were obtained from 70 patients who 
were undergoing surgical resection for primary MPM. In thirteen 
of these patients, a small amount of normal pleura tissue was used 
as a control. All samples were obtained and analysed in accord-
ance with procedures approved by the institutional review board 
of the University of California, San Francisco (IRB H8714–22 942–
01). The samples were fixed in formalin, embedded in paraffin in 
4-μm tissue microarray sections and immunostained as previously 
described.21 The tissue microarray slides were dewaxed with xy-
lene after 2 hours of baking at 60°C, dehydrated with ethanol, 
blocked with 3% hydrogen peroxide solution for 10 minutes and, 
then, placed into antigen retrieval solution at pH 8.0 (95°C, the 
repair time was 15 minutes). After being washed in PBS 3 times, 
the primary antibody was added and the slides were incubated at 
4°C overnight. The next day, the secondary antibody was added 
and the slides were incubated at 37°C for 30 minutes, and then 
DAB stained for 5 minutes. Finally, the slides were counterstained 
with haematoxylin, dehydrated and mounted in Diatex. All slides 
were read by two independent, blinded researchers, using a low-
power objective lens (20 ×) with a Zeiss Axioscop 2 microscope 
(Carl Zeiss Inc). The following scoring system was used: −, no stain; 
+, weak staining (≥10% and < 30% stained cellularity considered as 
positive); ++, moderate staining (≥30% and < 50% stained cellular-
ity considered as positive); and +++, strong staining (50% or above 
stained cellularity considered as positive).
2.3 | RNA isolation, cDNA synthesis and 
quantitative real-time RT-PCR
The RNeasy Mini kit (Qiagen) was used for total RNA extraction from 
MPM cells. The cDNA was transcribed using iScript-cDNA Synthesis 
Kits (Bio-Rad) and then used as the template for real-time PCR, ac-
cording to the manufacturer's protocol. The TaqMan Biosystems 
7000 sequence detection system (Applied Biosystems) was used 
for real-time PCR detection. Expression of CDK7, YAP and the en-
dogenous control gene beta-glucuronidase (GUSB) was detected 
using commercially available primers and probe sequences (Applied 
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Biosystems) and analysed using Relative Quantification Software 
(Applied Biosystems).
2.4 | siRNA and plasmid DNA transfection
The cells were cultured in a 75-cm2 flask and seeded in 6-well plates 
at 2-4 × 104 per well for 24 hours before treatment so that the cell 
density reached 50%-70%. Non-targeting siRNA was used as control 
(sc-37007, Santa Cruz Biotechnology). Two CDK7 siRNAs were used 
to treat the cells. One was the SMARTpool siRNA targeting CDK7 
(CDK7 siRNA-1) purchased from Thermo Scientific Dharmacon, and 
the other was CDK7 siRNA targeting the 3′UTR end of the CDK7 
gene (CDK7 siRNA-2) purchased from Life Technologies (AM16708, 
Grand Island, NY, USA). According to the protocol, cells were 
transfected with 4 μg of CDK7 plasmid DNA (Addgene #16467, 
Cambridge, MA) using Lipofectamine 3000 (Invitrogen) transfec-
tion reagent and 100 nmol/L siRNA using Lipofectamine RNAiMAX 
(Invitrogen). After transfection for 48 hours, the cells were har-
vested for further analysis.
2.5 | Luciferase reporter assay
Cell lines were co-transfected with the 8 × GTIIC-luciferase plas-
mid (Addgene) and Renilla luciferase pRL-TK plasmid (Promega). The 
transfection reagent was Lipofectamine 3000 (Invitrogen). After 
being cultured for 48 hours, the cells were harvested and trans-
ferred into a 96-well plate for analysis using the Dual-Luciferase 
Reporter Assay Kit (Promega). Luminescent signalling was detected 
on a GloMax-96 Microplate Luminometer (Promega) according to 
the manufacturer's instructions. We performed the experiments 
three times.
2.6 | Western blot analysis
The primary antibodies for CDK7, YAP, phosphor-YAP (Ser127), 
cyr61, CTGF and Tead4 used in Western blot analysis were pur-
chased from Cell Signaling, Inc. NF/Merlin antibody was pur-
chased from LSBio. Total protein was extracted from cell lines 
using the Mammalian protein extraction kit (M-PER, Thermo), 
and nuclear/cytoplasm proteins were extracted using a nuclear/
cytoplasm extraction kit (Thermo Fisher Scientific Inc) accord-
ing to the manufacturers' protocols. The protein concentrations 
were measured using the Pierce BCA Protein Assay Kit (Thermo 
Fisher Scientific Inc). Total protein for each sample was 15 μg, and 
the samples were run on 4%-20% gradient SDS-polyacrylamide 
gels (Bio-Rad Laboratories, Inc). After proteins were transferred 
to Immobilon-P nitrocellulose membranes (Millipore), the mem-
branes were blocked in 5% non-fat milk and then probed with the 
primary antibodies overnight at 4°C. The membranes were incu-
bated with HRP-conjugated secondary antibodies for 1 hour at 
room temperature and detected by using an ECL blotting analysis 
system (Amersham Pharmacia Biotech). We performed the experi-
ments three times.
2.7 | Protein degradation assay
Malignant pleural mesothelioma cell lines 211H, H2052 and H290 
cultured in 6-well plates were subjected to the protein degradation 
assay, which were performed three times. We divided each cell line 
into two groups: control siRNA-treated and CDK7 siRNA-treated. 
Both groups were transfected with siRNA at a concentration of 
100 nmol/L for 48 hours using Lipofectamine RNAiMAX (Invitrogen). 
The medium (1% FBS) was then changed, and 100 μg/mL cyclohex-
imide (Sigma), an inhibitor of protein synthesis, was added. After 
treatment, the cells were harvested at six different time points: 0, 
1, 2, 4, 6 and 8 hours. Total protein was extracted from cells and 
analysed by Western blot.
2.8 | Transwell invasion assay
The 6-transwell plate system (Corning Incorporated) was used 
to perform a transwell invasion assay in 211H, H2052 and H290 
cell lines. The transwell inserts were coated with 500 µL matrigel 
and incubated at 37°C at for one hour. Control siRNA and CDK7 
siRNA were used to transfect respectively using Lipofectamine 
RNAiMAX (Invitrogen). After being cultured 48 hours, cells were 
harvested, and 2 × 105 cells were resuspended in serum-free me-
dium and transferred into the upper chamber of the transwell. A 
total of 2.5 mL medium (10% FBS) was added to the lower chamber. 
The transwell was incubated at 37°C for 20 hours, at which point 
the matrigel and cells were wiped out. After formalin fixation and 
methanol permeabilization, the insert membrane was stained with 
Crystal Violet (Sigma-Aldrich) for 20 minutes. Phase contrast im-
ages were obtained, and the cells on the lower side of the membrane 
were counted in six random visual fields under a 20× objective lens.
2.9 | Tumorsphere assay
H290 cells cultured in the flask to 80% confluence were trypsinized 
to prepare single-cell suspensions (one cell per μL), which were 
treated with 100 µmol/L THZ1 (a Cdk7 inhibitor) (CAS# 1604810-
83-4, Cayman CHEMICAL) or DMSO (0.05%) for 24 hours in StemPro 
MSC SFM Basal Medium CTS + StemPro MSC SFM Supplement CTS 
(Life Technologies), 2 nmol/L l-glutamine and penicillin (100 IU/mL). 
Then, 2 × 103 cells per well were plated in an ultra-low 12-well at-
tachment plates (Corning Incorporated). Cells were cultured for 
10 days. Then, 100 μL of medium was added into each well every 
2-3 days. Tumorspheres that formed in non-adherent cultures were 
counted under a 10× objective lens. The cut-off size for the spheres 
counted was 60 µm.
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2.10 | Co-immunoprecipitation (co-IP) analysis
Protein extraction and co-IP analysis were conducted using the 
Pierce™ Co-Immunoprecipitation Kit (Cat#26149, Thermo Fisher). 
Antibodies used for co-IP included a YAP antibody (Cat#14074, 
Cell Signaling) and IgG antibody (Cat#2729, Cell Signaling). Bound 
proteins were analysed by 8% SDS-PAGE and Western blot. 
Membranes were blocked with PBS containing 0.1% Tween-20 
and 5% (w/v) skim milk, followed by incubation with YAP anti-
body (Cat#14074, Cell Signaling), CDK7 antibody (Cat#2916, Cell 
Signaling) and Tead4 antibody (ab50945, Abcam). Signals were de-
tected using SuperSignal West Pico Chemiluminescence Substrate 
(Thermo Scientific). Where applicable, signal intensities were quan-
tified by ImageJ densitometry analysis software (version 1.52r).
2.11 | Statistical analysis
Data are expressed as the mean ± standard deviation (SD). All sta-
tistical analyses were performed using the SPSS 23.0 for Windows 
software system (SPSS Inc). One-way ANOVA were used to com-
pare the differences among multiple groups. Student's t test was 
used to evaluate the statistical significance of differences between 
two groups. The correlation analysis was determined by Spearman 
product correlation. Statistical significance was defined as P < .05 
(*P < .05, **P ≤ .01, ***P ≤ .001), based on two-tailed tests.
3  | RESULTS
3.1 | CDK7 and YAP are co-expressed in MPM 
tissues
To evaluate the expression of YAP and CDK7 in MPM tissues, we 
analysed 70 MPM samples and 13 normal pleural samples by IHC 
(Figure 1). The positive rates of YAP and CDK7 expression in the 
MPM samples were 68.5% (48/70) and 72.9% (51/70), respectively. 
Forty-one samples (58.6%) were positive for expression of both pro-
teins, accounting for 85.4% of YAP-positive samples and 80.4% of 
CDK7-positive samples, respectively (Tables 1 and 2). The ratio of 
YAP-positive cells in CDK7-positive samples was significantly higher 
than that in CDK7 negative samples (X2 = 12.182, P < .001). No nor-
mal pleural samples showed YAP or CDK7 positivity (Table 3). Then, 
we also found the NF2 loss is about 45.7% (32/70) of mesothelio-
mas, and YAP and CDK7 expressions are not correlated with NF2 
loss in our mesothelioma TMA array (r = −.093, P = .443; r = −.062, 
P = .608, respectively) (Tables S1-S3). Further analysis showed that 
YAP and CDK7 were positively correlated (n = 70, r = .513, P < .001).
F I G U R E  1   Immunohistochemistry of 
CDK7 and YAP in human malignant pleural 
mesothelioma (MPM) Representative 
image showing expression of YAP protein 
(A) and CDK7 protein (B) in human 
MPM tissues and normal pleural tissues 
analysed by immunohistochemistry. (A: 
1-2) and (B: 1-2) are normal pleural tissues. 
(A: 3-8) and (B: 3-8) are MPM tissues. (A: 
4, 6, 8) Staining of YAP was localized to 
the nuclei (arrows), and (B: 4, 6, 8) staining 
of CDK7 was also localized to the nuclei 
(arrows) under a 20× objective lens. – and 
+ indicate negative; ++ and +++ indicate 
positive
     |  1091MIAO et Al.
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3.2 | CDK7 expression level is consistent with 
activity of the Hippo pathway (YAP) in MPM cell lines
Cyclin-dependent kinase 7 is a subunit of the transcriptional initia-
tion factor II-H (TFIIH), and YAP is the transcriptional coactivator.22 
Our IHC results implied that there may be some relationship be-
tween YAP and CDK7, which we further investigated in six MPM cell 
lines (211H, H290, H2452, H2052, MS-1 and H28) and one normal 
mesothelial cell line (LP-9). The Western blot results showed that 
the protein expression level of CDK7 in 211H, H290, H2052 and 
MS-1 cells was higher than in H2452 and H28 cells (Figure 2A,B). We 
used the GTIIC-luciferase reporter construct to evaluate the activity 
of YAP-TEAD-mediated transcription23 in these cell lines and found 
higher activity in 211H, H290, H2052 and MS-1 cells than in H2452 
and H28 cells (P < .05, Figure 2C). Malignant pleural mesothelioma 
cell lines with relative higher CDK7 expression showed higher GTIIC 
reporter activity. Phosphorylation of YAP (S127) through LATS1/2 
promotes YAP translocation from the nucleus to the cytoplasm 
followed by YAP protein degradation. The ratio of YAP/pYAP pro-
tein expression in 211H and H290 cell lines was higher than that of 
other cell lines (Figure S1). The YAP/pYAP ratio in H2052 and MS-1 
cell lines was lower than in 211H and H290 cells but higher than in 
H2452 and H28 cells.
3.3 | GTIIC reporter activity and YAP protein 
expression were down-regulated by CDK7 inhibition
We then investigated whether CDK7 suppression affects GTIIC 
reporter activity in 211H, H2052 and H290 cell lines. Two CDK7 
siRNAs (3′ and 5′) were used to silence the CDK7 gene. Compared 
with that of the cells treated with control siRNA, the reporter ac-
tivity of these three cell lines decreased significantly after CDK7 
silencing (Figure 3A-C, P < .05). We next investigated whether in-
hibition of CDK7 influences YAP protein levels. After 48 hours of 
treatment with two CDK7 siRNAs in 211H, H2052 and H290 cell 
lines, the efficiency of CDK7 inhibition was assessed by Western 
blotting. Compared with cell lines treated with control siRNA, the 
YAP expression level in the CDK7-siRNA-treated cell lines clearly 
decreased (Figure 3D). We also investigated the protein level of 
YAP downstream genes (Cyr61 and CTGF) after knockdown of 
CDK7 with siRNAs in the 211H, H2052 and H290 cell lines. The 
results indicated that CDK7 deprivation significantly reduced the 
protein levels of both genes in these cell lines (Figure 3D).
3.4 | CDK7 inhibition has no influence on the mRNA 
level of YAP, but promotes YAP degradation
The effect of CDK7 on YAP protein levels may be the regulation of 
YAP mRNA or the degradation of YAP protein. Using semi-quanti-
tative real-time PCR (RT-PCR), we detected the mRNA level in the 
H290 cell line. We then used two CDK7 siRNAs (3′ and 5′) to si-
lence the CDK7 gene. The mRNA levels of YAP did not decrease as 
CDK7 did (Figure 4A,B). We then performed a protein degradation 
experiment in the 211H, H290 and H2052 cell lines. In the control 
siRNA-treated group, the half-life of YAP protein in 211H cells was 
approximately 8 hours. The YAP protein level in H2052 cells did not 
decrease within 8 hours, and that in H290 cells decreased slightly 
at 8 hours (Figure 4C-E). In the CDK7 siRNA-treated group, the YAP 
protein levels in 211H, H290 and H2052 cells were significantly 
  
CDK7
X2 P value
Positive
(++/+++)
Negative
(∓) Total
YAP Positive
(++/+++)
41 7 48   
Negative
(∓)
10 12 22   
Total  51 19 70 12.182 <.001
Note: − = no stain; + = weak stain; ++ = moderate stain; +++ = strong stain; ++/+++ = positive; 
∓ = negative. Correlation: r = .513, P < .001
TA B L E  2   YAP and CDK7 IHC 
comparison in 70 human malignant pleural 
mesothelioma tissues
  
CDK7
Positive (++/+++) Negative (∓) Total
YAP Positive (++/+++) 0 0 0
Negative (∓) 0 13 13
Total  0 0  
Note: − = no stain; + = weak stain; ++ = moderate stain; +++ = strong stain; ++/+++ = positive; 
∓ = negative.
TA B L E  3   CDK7 and YAP IHC 
comparison in normal human pleural 
tissues
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decreased at 4, 6 and 2 hours, respectively (Figure 4C-E). Compared 
with the control siRNA group, the half-life of the YAP protein in 
these three cell lines was significantly shortened. These results sug-
gested that inhibition of CDK7 promoted YAP protein degradation 
in MPM cell lines.
3.5 | Knockdown of CDK7 decreased invasion and 
tumorsphere formation ability in MPM cell lines
The results of the transwell invasion assay showed that knock-
down of CDK7 significantly decreased the invasion ability of 
211H, H2052 and H290 cells to 57.5%, 63.4% and 52.1%, re-
spectively, normalized to the number of cells treated with control 
siRNA (P < .001) (Figure 5A-D). In the tumorsphere formation ex-
periment, H290 cells formed compact spheres, but the 211H and 
H2052 cells did not. The reason for this is unknown. The results 
showed that an average of 10 000 H290 cells treated with DMSO 
formed 45 spheres larger than 60 µm. In 10 000 H290 cells treated 
with THZ1, the average compact sphere decreased significantly to 
12 (Figure 5E-G) (P < .001). Collectively, these results indicated 
that CDK7 inhibition significantly impaired the invasion ability of 
211H, H290 and H2052 cells and the self-renewal ability of the 
H290 cell line.
3.6 | YAP protein expression level was rescued 
by forced restoration of the CDK7 gene under 
CDK7 inhibition
To further verify the relationship between YAP and CDK7, YAP pro-
tein expression level was tested after CDK7 inhibition and/or forced 
restoration of the CDK7 gene in 211H and H2052 cells. The CDK7 
siRNA targeting the 3′UTR was used to knockdown CDK7, and the 
CDK7 plasmid DNA was used to overexpress CDK7. Western blot 
was used to evaluate the protein level. After CDK7 inhibition, the 
YAP protein level was reduced in both cell lines (Figure 6A,B), similar 
to what occurred after CDK7 inhibition using a pooled CDK7 siRNA. 
Furthermore, to confirm that the decreased YAP expression was 
caused by CDK7 inhibition, we evaluated the YAP expression level 
under forced CDK7 restoration in 211H and H2052 cells treated 
with CDK7 3′UTR siRNA. The results showed YAP protein level was 
increased after forced CDK7 restoration (Figure 6A,B).
3.7 | Binding of CDK7 and YAP proteins in 
MPM cells
As a protein serine/threonine kinase, CDK7 participates in reg-
ulation of cell proliferation and differentiation in many ways. 
Phosphorylation of transcription factors is one way by which CDK7 
regulates gene expression, including p53, retinoid receptors and 
oestrogen receptor. To test the hypothesis that CDK7 protein in-
teracts with YAP protein, we used co-IP in 211H cells and evaluated 
protein levels by Western blot. Using a YAP monoclonal antibody re-
sulted in capture of CDK7 protein. Control co-IP assays using Rabbit 
IgG showed no YAP or CDK7 protein expression (Figure 6C). These 
findings suggested that there is direct binding between CDK7 and 
YAP protein in MPM cells (Figure 6D).
F I G U R E  2   Expression of CDK7 and YAP in MPM cell lines. A, 
Western blot was used to detect levels of CDK7, YAP and pYAP 
in MPM cell lines. GAPDH was used as a loading control. Band 
intensity was analysed with ImageJ software and normalized to 
the intensity of the GAPDH band. The numbers below are YAP/
pYAP ratio. B, CDK7 protein expression in MPM cell lines based 
on Western blot intensity. C, GTIIC reporter activity of the Hippo 
pathway in MPM cell lines; the LP-9 cell line was used as a control 
(F = 38.017; P < .001) (vs LP-9: *P < .05, **P ≤ .01, ***P ≤ .001, One-
way ANOVA, Scheffe multiple comparisons)
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4  | DISCUSSION
The results of our study suggested that CDK7 has previously unrec-
ognized effects on YAP in MPM cells. Several lines of evidence sup-
port that CDK7 inhibition down-regulates YAP protein expression in 
MPM cells. First, in MPM tissue, IHC staining indicated that CDK7 
and YAP expression were positive correlated. Second, inhibition of 
CDK7 decreased the YAP protein expression level and the GTIIC re-
porter activity of the Hippo pathway in MPM cell lines. Moreover, 
the YAP protein expression level was rescued by forced restoration 
of the CDK7 gene after knockdown the CDK7 gene in 211H and 
H2052 cell lines. Third, CDK7 inhibition accelerated degradation of 
YAP protein. Fourth, inhibition of CDK7 reduced the migration, inva-
sion and tumorsphere formation ability of 211H, H290 and H2052 
cells. Finally, our co-IP using an anti-YAP antibody captured CDK7 
protein in 211H cells. The experiments were performed at least 
three times.
The correlation between CDK7 and YAP, which has important ef-
fects on MPM cell self-proliferation and tumorigenesis, respectively, 
has not been evaluated before. In our study, CDK7 and YAP were 
co-expressed in MPM tissues. A recent study24 reported the overex-
pression of the CDK7 gene in MPM, which is supported by our find-
ings that the positive rate of CDK7 expression in MPM samples was 
72.9% (51/70). At the same time, YAP staining in the nucleus was 
moderate to strong in 68.6% (48/70) of samples. Abnormalities in 
the Hippo/YAP pathway are key factors for MPM to maintain tumour 
cell invasion and malignant biological characteristics.9,25 However, 
YAP and CDK7 co-expression in MPM has not been reported before. 
F I G U R E  3   GTIIC reporter activity 
and the protein levels of CDK7, YAP and 
YAP downstream genes in MPM cell lines 
after knockdown of CDK7. GTIIC reporter 
activity was measured in three cell lines 
after CDK7 inhibition by siRNA1, 2. A, 
211H cells. B, H2052 cells. C, H290 cells. 
D, The protein expression of CDK7, YAP, 
pYAP and YAP downstream genes (Cyr61 
and CTGF) was detected by Western 
blot after CDK7 inhibition by siRNA1, 
2. Expression was compared with their 
respective control cells treated with 
non-targeting siRNA (vs siRNA-ctrl group, 
*P < .05, **P ≤ .01, ***P ≤ .001, One-way 
ANOVA, Scheffe multiple comparisons). 
GAPDH was used as a loading control. 
Band intensity was analysed with ImageJ 
software and normalized to the intensity 
of the GAPDH band
     |  1095MIAO et Al.
In our study, this co-expression was observed in 58.6% (41/70) of 
MPM samples and correlated positive significantly (n = 70, r = .513, 
P < .001). In addition, the results of further cytological experiments 
in MPM cells using two CDK7-siRNAs showed that the expression 
level of YAP can be reduced by CDK7-siRNAs. Moreover, that de-
crease in YAP protein expression caused by CDK7 inhibition was 
rescued by forced CDK7 restoration. These findings mean that the 
expression of YAP was regulated by CDK7 in MPM.
How CDK7 affects the level of YAP protein expression is another 
question we sought to answer. Our results show that CDK7 inhibi-
tion accelerated the degradation of YAP protein. In the Hippo path-
way, YAP is negatively regulated by MST1, MST2, LATS1 and LATS2 
kinases26-30 through modulated phosphorylation events of kinase 
cascade in most situations. In addition, YAP activity or function is 
regulated by many factors that do not influence the LATS/MST ki-
nase activity31 and have crosstalk with other pathways.32,33 CDK7 
regulates transcription primarily by phosphorylating serine 5 at the 
C-terminal domain of RNA polymerase II, as well as transcription fac-
tors such as oestrogen receptor-α.34,35 The manner in which CDK7 
regulates YAP stability has not been reported. Our protein degra-
dation experiment showed that after MPM cells were treated with 
the protein inhibitor cycloheximide under CDK7 inhibition by siRNA, 
and YAP protein degradation was accelerated at different times 
compared with controls. Moreover, co-IP using a YAP monoclonal 
antibody captured CDK7 protein. The acceleration of YAP protein 
degradation may not be related to NF2 mutation and LAST2 deletion 
because this phenomenon exists in 211H, H290 and H2052 cell lines. 
In these three cell lines, there were reportedly different genetic inac-
tivation of Hippo pathway components, respectively, including NF2 
inactivation in H290 cells, LATS2 deletion in 211H cells, and both the 
mutation of NF2 and LAST2 in H2052 cells.36 And there was no cor-
relation between NF2 and nuclear YAP or CDK7 expression in MPM 
tissues. Yes-associated protein activity may also be regulated by many 
other pathways that do not influence NF2 activity.37,38 More tissue 
samples may be needed for the correlation analysis. Understanding 
the specific mechanisms requires further study of other upstream 
regulators of YAP and the different CDK7 activities because of the 
diversity of YAP regulation and the complexity of CDK7 function.
Several groups reported YAP overexpression promotes epithelial 
to mesenchymal transition (EMT) in cancer cell lines.39 Recently, the 
CDK7 inhibitor THZ1 was suggested to increase the stability of Snail 
protein in colorectal cancer cell lines,40 and THZ1 was thought to 
suppress TGFβ2-mediated EMT in lens epithelial cells.41 MPM has 
three pathological subtypes, epithelial, sarcomatoid and biphasic. 
F I G U R E  4   Analysis of YAP mRNA 
and protein expression levels after 
CDK7 inhibition in MPM cells. A, CDK7 
mRNA and (B) YAP mRNA levels in H290 
cells after CDK7 inhibition by siRNA1, 
2 were measured using qRT-PCR (vs 
siRNA-control group, *P < .05, **P ≤ .01, 
***P ≤ .001, One-way ANOVA, Scheffe 
multiple comparisons). C-E, Degradation 
of YAP protein was analysed in three 
MPM cell lines after CDK7 inhibition by 
Western blot. C, 211H cells. D, H2052 
cells. E, H290 cells. GAPDH was used 
as a loading control. Band intensity was 
analysed with ImageJ software and 
normalized to the intensity of the GAPDH 
band
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H2052 (sarcomatoid) and 211H (biphasic) have a mesenchymal phe-
notype that has invasion ability. We analysed two EMT markers 
(Snail and MMP9) with Western blotting in H2052 shControl cells 
and H2052 shCDK7 cells and found no dramatic differences at the 
protein level (data not shown).
Cyclin-dependent kinase 7 may be involved in cancer stem cell 
self-proliferation and differentiation.42,43 Our research on MPM 
also supports this view. The results of our tumorsphere formation 
assay showed that THZ1 suppressed sphere formation in H290 cell 
lines. This finding indicated that, in MPM, the inhibition of CDK7 
may suppress tumour development at least in part through the 
suppression of cancer stem cells. Our previous studies9,44,45 con-
firmed that the YAP protein is involved in the occurrence and de-
velopment of MPM and NSCLC, and its inhibitors can effectively 
inhibit cancer stem cell self-proliferation. The mutual relationship 
and influence mechanism of CDK7 and YAP in MPM requires fur-
ther study. Cyclin-dependent kinase 7 is a promising therapeutic 
approach for human MPM.
Taken together, the results of our study suggest that CDK7 
inhibition down-regulates YAP expression via promoting its deg-
radation and suppresses the migration and invasion of MPM cells. 
In addition, co-IP using a YAP-specific monoclonal antibody cap-
tured CDK7 protein. Our results provide new preliminary insights 
about the relationship between CDK7 and Hippo/YAP that will be 
helpful for understanding the development mechanism of MPM 
and provide ideas for further targeted therapy. Small molecule 
CDK7 inhibitors such as THZ1 may be beneficial for the treatment 
of patients with MPM. Further pre-clinical and clinical studies are 
warranted.
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